Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma
Phase 2
Terminated
- Conditions
- Neuroendocrine Carcinoma
- Interventions
- Registration Number
- NCT03168594
- Lead Sponsor
- Peking University
- Brief Summary
The study will be conducted to compare the safety and efficacy of irinotecan combined with cisplatin (IP regimen) and etoposide combined with cisplatin (EP regimen) in advanced or metastatic gastrointestinal pancreatic and esophageal neuroendocrine carcinoma.
In this prospective randomized phase II study, the investigators aim to compare the survival benefit as well as the safety for irinotecan combined with cisplatin (IP regimen) versus etoposide combined with cisplatin (EP regimen) in advanced or metastatic gastrointestinal pancreatic and esophageal neuroendocrine carcinoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
- sign written informed consent form
- age ≥ 18 years
- pathologically confirmed poorly-differentiated neuroendocrine carcinoma, G3(Ki67>20%);
- No prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune therapy or target therapy. For recurrent patients after radical surgery, adjuvant chemotherapy should not include irinotecan, cisplatin or etoposide, and the last date should beyond 6 months prior to randomization;
- At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan >=20mm, spiral CT scan >=10mm, no prior radiation to measurable lesions);
- Screening laboratory values must meet the following criteria (within past 7 days): hemoglobin ≥ 9.0 g/dL; neutrophils ≥ 1500 cells/ μL; platelets ≥ 100 x 10^3/ μL; total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum creatinine ≤1╳ULN;
- KPS ≥ 70;
- Predicted survival >=3 months;
- Negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women;
- Sexually active males or females willing to practice contraception during the study until 30 days after end of study.
Exclusion Criteria
- Hypersensitivity to IRI, DDP, VP-16,5-HT3 receptor antagonists;
- Prior antitumor therapy (including corticosteroids and immunotherapy) or participation in other clinical trials within past 4 weeks, or have not recovered from toxicities since the last treatment;
- Received surgery within past 4 weeks, or have not recovered from surgery;
- Severe diarrhea;
- Concurrent severe infection；
- Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including severe liver disease (active hepatitis, cirrhosis), uncontrolled diabetes or hypertension, or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm);
- Prior long term steroid therapy (excluding short term steroid treatment which is completed prior to > 2 weeks of study enrollment)；
- Meningeal carcinomatosis;
- Patients with central nervous system(CNS) disorder or peripheral nervous system disorder or psychiatric disease；
- Known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and hypertension, or congestive heart failure, or cardiac infarction within 6 months prior to study enrollment, or cardiac insufficiency；
- Pregnant or nursing, or sexually active males or females refuse to practice contraception during the study until 30 days after end of study;
- History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible；
- Person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons；
- Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A:Irinotecan combined with cisplatin (IP regimen) irinotecan cisplatin patients in arm A will receive chemotherapy of IP regimen: Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W B:Etoposide combined with cisplatin (EP regimen) Etoposide cisplatin patients in arm B will receive chemotherapy of EP regimen: Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
- Primary Outcome Measures
Name Time Method Overall response rate (ORR) From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months CT/MRI will be performed every 2 cycles of treatment by RECIST 1.1
- Secondary Outcome Measures
Name Time Method Incidence of Treatment-Emergent Adverse Events （Safety and Tolerability） From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Progression-free survival baseline, every 8 weeks up to 1 year after last patient first treatment Progression-free survival is defined as the time from the date of first dose to the date of the first documented radiological progression or death due to any cause
Overall survival baseline, every 8 weeks up to 1 year after last patient first treatment Overall survival is defined as the time from date of start of treatment to date of death due to any cause
Trial Locations
- Locations (1)
Beijing Cancer Hospital
🇨🇳Beijing, Beijing, China